This month, Intellect initiated a sponsored research collaboration with one of the foremost Alzheimer's disease research centers in the United States to examine the detailed molecular mechanism affecting propagation of tau pathology. The sponsored research collaboration is to support our efforts to develop our TauC3 monoclonal antibody as a therapeutic treatment for Alzheimer's disease and other tauopathies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.